Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project

Blood (2024) 144 (Supplement 1): 787.

https://doi.org/10.1182/blood-2024-204867

Published: 2024

Journal Articles

The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC

Blood (2024) 144 (Supplement 1): 405.

https://doi.org/10.1182/blood-2024-210022

Published: 2024

Journal Articles

The Use of Post-Transplant Cyclophosphamide Leads to Increased Cardiac Complications without Affecting Survival in Haploidentical Stem Cell Transplantation

Tommy Alfaro, Nihar Desai, Maria Queralt Salas, Carol Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Law, Jeffrey H. Lipton, Fotios Michelis, Igor Novitzky-Basso, Jonas Mattsson, Auro Viswabandya

Blood (2024) 144 (Supplement 1): 7289.

https://doi.org/10.1182/blood-2024-205817

Published: 2024

Journal Articles

Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)

Blood (2024) 144 (Supplement 1): 3531.

https://doi.org/10.1182/blood-2024-203251

Published: 2024

Journal Articles

Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Blood (2024) 144 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2024-207118

Published: 2024

Journal Articles

Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 2108.

https://doi.org/10.1182/blood-2024-205181

Published: 2024

Journal Articles

Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 2105.

https://doi.org/10.1182/blood-2024-203054

Published: 2024

Journal Articles

Outcomes of 9/10 Mmud Allo-HCT Using Ptcy-TK Prophylaxis. Results from a Single Institution

Filipe Pinto, Alexandra Pedraza, Maria Suarez-Lledo, Laia Guardia, Paola Charry, Joan Cid, Miquel Lozano, Gerard Corrius, Noemí De Llobet, Enric Carreras, Laura Rosiñol Dachs, Francesc Fernández-Avilés, Montserrat Rovira, Carmen Martinez, Maria Queralt Salas, Jordi Esteve Reyner

Blood (2024) 144 (Supplement 1): 7342.

https://doi.org/10.1182/blood-2024-207563

Published: 2024

Journal Articles

HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 598.

https://doi.org/10.1182/blood-2024-205686

Published: 2024

Journal Articles

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

Blood (2024) 144 (Supplement 1): 4884.

https://doi.org/10.1182/blood-2024-204722

Published: 2024

Journal Articles

Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion

Tommy Alfaro, Nihar Desai, Carol Chen, Maria Queralt Salas, Igor Novitzky-Basso, Wilson Lam, Ivan Pasic, Arjun Datt Law, Fotios Michelis, Jeffrey H. Lipton, Armin Gerbitz, Rajat Kumar, Dennis Dong Hwan Kim, Jonas Mattsson, Auro Viswabandya

Blood (2024) 144 (Supplement 1): 2183.

https://doi.org/10.1182/blood-2024-199206

Published: 2024

Journal Articles

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Blood (2024) 144 (Supplement 1): 3423.

https://doi.org/10.1182/blood-2024-208083

Published: 2024

Journal Articles

Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

Blood (2024) 144 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2024-205568

Published: 2024

Journal Articles

Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 5148.

https://doi.org/10.1182/blood-2024-210442

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Blood (2023) 142 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2023-179852

Published: 2023

Journal Articles

Use of Pre-Transplant Minicog Cognitive Impairment Screening and Validation of Frailty and Functionality Assessment Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Tommy Alfaro, Maria Queralt Salas, Eshetu Atenafu, Ora Bascom, Leeann Wilson, Carol Chen, Arjun D. Law, Armin Gerbitz, Auro Viswabandya, Fotios Michelis, Jeffrey H. Lipton, Wilson Lam, Igor Novitzky-Basso, Dennis (Dong Hwan) Dong Hwan Kim, Jonas Mattsson, Ivan Pasic, Rajat Kumar

Blood (2023) 142 (Supplement 1): 5094.

https://doi.org/10.1182/blood-2023-191009

Published: 2023

Journal Articles

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2023-181076

Published: 2023

Journal Articles

Frailty Syndrome in Adults Undergoing Autologous Hematopoietic Cell Transplantation. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Blood (2023) 142 (Supplement 1): 3702.

https://doi.org/10.1182/blood-2023-185679

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Blood (2023) 142 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2023-174115

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

Blood (2023) 142 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2023-186687

Published: 2023

NARROW

Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project

The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC

The Use of Post-Transplant Cyclophosphamide Leads to Increased Cardiac Complications without Affecting Survival in Haploidentical Stem Cell Transplantation

Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)

Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Outcomes of 9/10 Mmud Allo-HCT Using Ptcy-TK Prophylaxis. Results from a Single Institution

HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Use of Pre-Transplant Minicog Cognitive Impairment Screening and Validation of Frailty and Functionality Assessment Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Frailty Syndrome in Adults Undergoing Autologous Hematopoietic Cell Transplantation. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only